Inventor · disambiguated record
Julia Reid
Also filed as: REID JULIA · REID JULIA E
13 granted patents·17 pending applications·39 citations·filing 2002–2025
90Inventor score
Top patents by PatentIndex Score
30 records- 0195US12221656B2Methods and materials for assessing homologous recombination deficiencyMYRIAD GENETICS INC·Filed 2022·Granted Feb 11, 2025·3 cites·18 claims
- 0290US10876164B2Gene signatures for cancer prognosisMYRIAD GENETICS INC·Filed 2015·Granted Dec 29, 2020·5 cites·4 claims
- 0389US11174517B2Gene signatures for cancer prognosisMYRIAD GENETICS INC·Filed 2016·Granted Nov 16, 2021·4 cites·7 claims
- 0489US9976188B2Cancer biomarkersMYRIAD GENETICS INC·Filed 2017·Granted May 22, 2018·5 cites·8 claims
- 0588US10954568B2Gene signatures for cancer prognosisMYRIAD GENETICS INC·Filed 2015·Granted Mar 23, 2021·3 cites·4 claims
- 0688US2024182979A1Cancer biomarkersMYRIAD GENETICS INC·Filed 2024·Application pending·0 cites
- 0786US11505832B2Method of using biomarkers and clinical variables for predicting chemotherapy benefitMYRIAD GENETICS INC·Filed 2020·Granted Nov 22, 2022·2 cites·20 claims
- 0884US9605319B2Gene signatures for cancer diagnosis and prognosisSTONE STEVEN·Filed 2011·Granted Mar 28, 2017·6 cites·8 claims
- 0979US10519513B2Cancer BiomarkersMYRIAD GENETICS INC·Filed 2019·Granted Dec 31, 2019·1 cites·8 claims
- 1078US7195873B2Drug response marker in beta-1 adrenergic receptor geneMYRIAD GENETICS INC·Filed 2002·Granted Mar 27, 2007·9 cites·12 claims
- 1178US2022259675A1Gene signatures for cancer prognosisMYRIAD GENETICS INC·Filed 2022·Application pending·0 cites
- 1274US10400287B2Methods and materials for assessing homologous recombination deficiencyMYRIAD GENETICS INC·Filed 2017·Granted Sep 3, 2019·1 cites·6 claims
- 1373US2025179587A1Methods and materials for assessing homologous recombination deficiencyMYRIAD GENETICS INC·Filed 2025·Application pending·0 cites
- 1472US12421555B2Methods and materials for assessing homologous recombination deficiencyMYRIAD GENETICS INC·Filed 2018·Granted Sep 23, 2025·0 cites·10 claims
- 1572US12180551B2Method of using biomarkers and clinical variables for predicting chemotherapy benefitMYRIAD GENETICS INC·Filed 2022·Granted Dec 31, 2024·0 cites·20 claims
- 1670US2018334722A1Gene signatures for cancer prognosisMYRIAD GENETICS INC·Filed 2018·Application pending·0 cites
- 1769US2020056246A1Cancer biomarkersMYRIAD GENETICS INC·Filed 2019·Application pending·0 cites
- 1867US10501807B2Cancer biomarkersMYRIAD GENETICS INC·Filed 2018·Granted Dec 10, 2019·0 cites·8 claims
- 1966US2022112565A1Gene signatures for cancer prognosisMYRIAD GENETICS INC·Filed 2021·Application pending·0 cites
- 2062US2021071269A1Gene signatures for cancer prognosisMYRIAD GENETICS INC·Filed 2020·Application pending·0 cites
- 2158US2012053253A1Gene signatures for cancer prognosisSTONE STEVEN·Filed 2011·Application pending·0 cites
- 2256US2015232947A1Cancer biomarkersMYRIAD GENETICS INC·Filed 2015·Application pending·0 cites
- 2355US2016355884A1Gene signatures for cancer prognosisMYRIAD GENETICS INC·Filed 2016·Application pending·0 cites
- 2454US2017096712A1Gene signatures for cancer diagnosis and prognosisMYRIAD GENETICS INC·Filed 2016·Application pending·0 cites
- 2553US2012041274A1Cancer biomarkersSTONE STEVEN·Filed 2011·Application pending·0 cites
- 2653US2014170242A1Gene signatures for lung cancer prognosis and therapy selectionMYRIAD GENETICS INC·Filed 2014·Application pending·0 cites
- 2749US2014212415A1Hypoxia-related gene signatures for cancer classificationMYRIAD GENETICS INC·Filed 2014·Application pending·0 cites
- 2848US2007082347A1Gene variants and use thereofMYRIAD GENETICS INC·Filed 2006·Application pending·0 cites
- 2944US2014315935A1Gene signatures for lung cancer prognosis and therapy selectionMYRIAD GENETICS INC·Filed 2014·Application pending·0 cites
- 3040US2016281177A1Gene signatures for renal cancer prognosisMYRIAD GENETICS INC·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Julia Reid files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →